A Phase III Randomized, Multicenter, Multinational, Double-Masked,Placebo-Controlled Study of Photrex™ (Rostaporfin) PhotodynamicTherapy in the Treatment of Classic and Occult Subfoveal ChoroidalNeovascularization Associated with Age-Related Macular Degeneration
A Phase III Randomized, Multicenter, Multinational, Double-Masked, Placebo-Controlled Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Classic and Occult Subfoveal Choroidal Neovascularization Associated With AMD
The purpose of this study is to confirm the efficacy and safety of rostaporfin (PHOTREX) photodynamic therapy (PDT) in the treatment of classic and occult subfoveal choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).
100 项与 Miravant Medical Technologies 相关的临床结果
0 项与 Miravant Medical Technologies 相关的专利(医药)
100 项与 Miravant Medical Technologies 相关的药物交易
100 项与 Miravant Medical Technologies 相关的转化医学